No Data
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals Price Target Raised to $66.00/Share From $62.00 by Evercore ISI Group
Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Express News | Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}